The Technical Analyst
The Greater Cannabis [GCAN]
Exchange: PNK Industry: Drug Manufacturers
The Greater Cannabis Price, Forecast, Insider, Ratings, Fundamentals & Signals
-14.29% $0.0006
America/New_York / 3 mai 2024 @ 14:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.483 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 804.64 mill |
| Avg Daily Volume: | 3.99 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -6.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0004 (-158.39%) $-0.0010 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0006 - 0.0006 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2019-12-02 | Anderson Jimmy Wayne | Sell | 176 878 | Common Stock |
| 2019-11-27 | Anderson Jimmy Wayne | Sell | 195 080 | Common Stock |
| 2019-01-01 | Anderson Jimmy Wayne | Sell | 0 | Common Stock |
| 2019-01-01 | Anderson Jimmy Wayne | Buy | 0 | Common Stock |
| 2007-10-30 | Demedio David M | Sell | 225 000 | Stock Options |
| INSIDER POWER |
|---|
| 0.00 |
| Last 15 transactions |
| Buy: 1 975 000 | Sell: 1 096 958 |
Forecast:
15:42 - $0.0010
Live Trading Signals (every 1 min)
Forecast
1: 14:12 - $0.0010
Forecast 2: 15:02 - $0.0010
Forecast 3: 15:42 - $0.0010
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0006 (-14.29% ) |
| Volume | 10.42 mill |
| Avg. Vol. | 3.99 mill |
| % of Avg. Vol | 261.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GCAN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GCAN
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company was founded in 2014 and is based in Baltimore, Maryland.
Latest Press Releases
2024-02-27 07:45:00 - Press Release
Gcanrx Announces Completion Of Preclinical Study For Neuropsychiatric Cannabinoid Therapy
Baltimore, md, feb. 27, 2024 (globe newswire) -- greater cannabis company, inc. (“gcanrx” or the “company”) (otc: gcan) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy.
2023-09-21 08:29:00 - Press Release
Gcanrx Featured In American Journal Of Endocannabinoid Medicine
Baltimore, sept. 21, 2023 (globe newswire) -- greater cannabis company, inc. (“gcanrx” or the “company”) (otc: gcan) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that the company and its scientific advisor, dr. adi aran, has been featured in the american journal of endocannabinoid medicine (ajem).
2021-08-19 09:45:00 - Press Release
Gcanrx Signs Licensing Agreement With Shaare Zedek Scientific For Innovative Neuropsychiatric Cannabinoid Therapy
Baltimore, aug. 19, 2021 (globe newswire) -- greater cannabis company, inc. (“gcanrx” or the “company”) (otcqb: gcan) a cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has entered into a licensing agreement (the “agreement”) with shaare zedek scientific ltd. (“szs”), the technology transfer arm of jerusalem's shaare zedek medical center (szmc). the agreement covers the license of szs's novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, parkinson's disease, alzheimer's disease and other neuropsychiatric disorders. shaare zedek medical center, founded in 1901, is one of the largest multidisciplinary research hospitals in israel with 1,000 beds and over 850,000 patient visits a year...
2021-03-16 09:12:00 - Press Release
Gcanrx Announces Collaboration With Renowned Cannabis Research Lab
Baltimore, march 16, 2021 (globe newswire) -- greater cannabis company ( otcqb: gcan ), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products is proud to announce a collaboration with israel-based cannabis lab, phytor ltd, a leader in the research and development of plant-based therapeutics.
Latest News
2021-08-19 09:45:00 - GlobeNewsWire
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has entered into a licensing agreement (the “Agreement”) with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem's Shaare Zedek Medical Center (SZMC). The agreement covers the license of SZS's novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease and other neuropsychiatric disorders. Shaare Zedek Medical Center, founded in 1901, is one of the largest multidisciplinary research hospitals in Israel with 1,000 beds and over 850,000 patient visits a year...
2021-03-16 09:12:00 - GlobeNewsWire
GCANRx Announces Collaboration with Renowned Cannabis Research Lab
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company ( OTCQB: GCAN ), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products is proud to announce a collaboration with Israel-based cannabis lab, Phytor LTD, a leader in the research and development of plant-based therapeutics.